With the in-depth understanding of viral proteins glycosylation, carbohydrate-based antiviral vaccines for special viruses have attracted extensive attention. CD BioGlyco is working on carbohydrate synthesis and immunogenicity studies to provide scientific assistance to our clients all over the worldwide in the development of carbohydrate-based antiviral vaccines.
Carbohydrates usually exist on the surface of bacteria, fungi and viruses. In recent years, researchers have had a better understanding of the biological role of viral proteins N-glycosylation. Although highly variable glycans are essential for virus survival, some glycans with highly conserved structures are also crucial for virulence, which indicates that these highly conserved glycans can be used as targets for the development of vaccines and drugs. So far, the research of antiviral vaccines based on synthetic carbohydrates has mainly focused on the anti-HIV vaccine. The key challenges for effective immunization with carbohydrate-based HIV vaccines are the design and construction of multivalent glycans to induce multiple bnAbs and achieve broad protection.
In addition, glycan-based vaccines may also be a promising alternative method to prevent COVID-19 infections in the future. It is very important to investigate the rationable combination of these glycan-based vaccines to defeat the newly generated SRS-CoV-2 variants. An in-depth understanding of the immune activation pathways of different carbohydrates is critically important for the development of safe and effective carbohydrate-based vaccines.
Fig.1 Schematic representation of complex glycans in the interplay between virus and host. (Kumbhar, 2021)
CD BioGlyco has established a variety of carbohydrate-based vaccines design strategies to help our clients develop antiviral vaccines. Our services include but are not limited to:
We accelerate the synthesis of structurally well-defined carbohydrates through an automated solid-phase oligosaccharide synthesizer and enhance the immunogenicity of carbohydrates through a variety of methods.
We have made significant progress in 2G12-targeted vaccine design, PG9- and PG16-targeted vaccine design, and the development of carbohydrate-based HIV vaccines using reverse vaccinology approaches.
We take spike glycoprotein (S-protein) of SARS-CoV-2 as the key target of vaccine development to design vaccines that can protect against different variants.
As an accomplished biotechnology company in the field of glycoscience, CD BioGlyco has created a new platform for the design of carbohydrate-based vaccines for different types of viruses. We have the confidence to provide our customers with effective scientific assistance to accelerate their research. If you have a demand for our services, please contact us directly for more information.
Reference:
